Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...

Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...